Supplements for high-altitude travelers
Acetazolamide remains the gold standard for AMS prevention; the supplement layer is narrow and mostly about iron status and acclimatisation foundations.
The altitude-traveler stack — rationale by ingredient
Iron repletion (if ferritin is low) — start 6–8 weeks before departure
Hypoxic adaptation involves increased erythropoietin and red-cell production; iron-deficient travelers acclimatise worse and report more AMS symptoms. Check ferritin 6–8 weeks before a high-altitude trip; aim for a ferritin >30 ng/mL (some experts suggest >50 ng/mL for serious altitude objectives). Use ferrous bisglycinate (gentle iron) 25–50 mg elemental every other day for better absorption and tolerability than daily dosing.
Vitamin D3 to a 25-OH-D of 30–50 ng/mL
Foundational immune and muscle support. Particularly relevant in winter mountain travel from low-sun-exposure baselines.
Electrolyte complex (Na/K/Mg) at altitude
Altitude diuresis is real — increased urine output is part of the acclimatisation response and dehydration accelerates AMS. Pair fluid intake with electrolyte replacement, especially during exertion. Sodium-containing oral rehydration is better than plain water for active days.
Low-dose melatonin 0.3–1 mg before bed
Sleep is reliably disrupted at altitude. Low-dose melatonin (not the 5–10 mg consumer doses) is the best-evidenced sleep adjunct. Avoid the high-dose products — they sediment but don't improve circadian alignment and can produce next-day grogginess on summit days.
Rhodiola rosea — try if you're curious, but don't rely on it
The small AMS-prevention trial base is mixed. Reasonable to add at the standard 200–400 mg/day SHR-5 extract starting 1 week before ascent. Do not substitute for acetazolamide in high-risk profiles.
What to skip
- Ginkgo biloba for AMS prevention — older positive trials were not replicated by Gertsch's 2004 head-to-head with acetazolamide. Not recommended by WMS.
- "Oxygen tablets" and "altitude pills" with proprietary blends — typically sub-therapeutic doses of multiple ingredients with no controlled-trial backing.
- Coca-leaf products outside their region of origin — illegal in most countries; do not export.
- High-dose iron just before departure in non-deficient travelers — supplements without indication don't help and can produce GI symptoms that complicate hiking days.
- Stimulants (ephedra, synephrine, high-dose caffeine boluses) at altitude — cardiovascular risk is elevated by hypoxia; not appropriate as performance aids.
- "Sherpa formulas" and "Andean adaptogen" stacks — marketing rebrands of standard adaptogens with no specific altitude data.
Sources
- Luks AM, et al. Wilderness Medical Society clinical practice guidelines for the prevention and treatment of acute altitude illness: 2024 update. Wilderness Environ Med. 2024;35(1S):2S–19S.
- Gertsch JH, et al. Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ. 2004;328(7443):797. PMID: 15070635
- Govus AD, et al. Iron status in elite young athletes: interaction of energy availability and altitude exposure. Eur J Appl Physiol. 2014;114(4):745–755. PMID: 24390603
- Lippl FJ, et al. Hypobaric hypoxia causes body weight reduction in obese subjects. Obesity. 2010;18(4):675–681. PMID: 19696757
- Schoonman GG, et al. The headache during high altitude exposure: pathophysiology and clinical relevance. Cephalalgia. 2008;28(7):710–717.
- Ryan BJ, et al. Iron and altitude: effects of altitude exposure on iron metabolism. Eur J Appl Physiol. 2018;118(4):705–720. PMID: 29399742